TriangleIvonescimab (NCT06805617)
Ivonescimab trial for Salivary Gland Cancer (NCT06805617). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with recurrent, metastatic or unresectable salivary gland cancer, with recent progression or worsening symptoms. Prior oral VEGFR inhibitors or anti-PD-1 treatment are excluded; previous treatment is not required.
The idea: intravenous ivonescimab targets PD-1 and VEGF, aiming to release an immune brake and hinder tumor blood-vessel growth. Separate groups enroll adenoid cystic and other salivary cancers. Researchers measure tumor response and safety.
This phase 2 study plans 35 patients. Dana-Farber Cancer Institute sponsors it. Two Boston US sites are recruiting. Tumor tissue is requested when safe and feasible.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.